Description
Interceptor Spectrum Tasty Chews for Dogs 25-50 Lbs (11-22 Kg) is a monthly oral chewable tablet providing combined heartworm prevention and gastrointestinal parasite control for medium to large-breed dogs. Each tablet in this weight band contains 11.5 mg milbemycin oxime and 114 mg praziquantel, calibrated for dogs weighing 25.1 to 50 lbs (11 to 22 kg). The product is approved for dogs and puppies from six weeks of age meeting the minimum weight threshold for this variant.
Recommended for
Dogs and puppies weighing 25.1 to 50 lbs (11 to 22 kg) from 6 weeks of age.
Indication/Coverage
For dogs suffering from, or at risk from, mixed parasitic infections, Interceptor Spectrum Tasty Chews 25-50 Lbs addresses the following indications:
- Heartworm prevention: Prevention of heartworm disease caused by Dirofilaria immitis, administered once monthly to arrest larval development before adult worms establish in the pulmonary vasculature.
- Roundworm treatment: Treatment and control of adult Toxocara canis and Toxascaris leonina infections in the gastrointestinal tract.
- Hookworm treatment: Treatment and control of adult Ancylostoma caninum infections; a single dose of milbemycin oxime at 0.5 mg/kg achieved 99.6% efficacy against naturally acquired hookworm in FDA-submitted laboratory studies.
- Whipworm treatment: Treatment and control of adult Trichuris vulpis
- Tapeworm treatment: Treatment and control of adult Taenia pisiformis, Echinococcus multilocularis, and Echinococcus granulosus infections; praziquantel at 5 mg/kg demonstrated 100% efficacy against all three tapeworm species in separate controlled studies under NADA 141-338.
Key Benefits
The following clinical properties characterize this formulation for dogs in the 25.1 to 50 lbs weight range.
- Five-parasite coverage: One monthly chewable addresses heartworm, two roundworm species, hookworm, whipworm, and three tapeworm species, removing the need to administer separate nematocidal and cestocidal products on different schedules.
- Systemic nematocidal action: Milbemycin oxime binds to and opens glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, producing sustained paralysis in adult roundworm, hookworm, and whipworm populations without requiring contact application.
- Tegumental tapeworm disruption: Praziquantel increases cell membrane permeability in cestode tegument, causing rapid paralysis and gastrointestinal expulsion of adult Taenia and Echinococcus species within hours of dosing.
- Laboratory-confirmed heartworm prevention: In a pivotal FDA study, six consecutive monthly doses delivered 100% effectiveness against experimentally induced immitis infection, with zero adult worms recovered from treated dogs at necropsy.
- Weight-band accuracy at this range: The 25-50 lbs tablet delivers milbemycin oxime at 0.23 to 0.46 mg/lb (0.5 to 1.0 mg/kg) across the full weight band, maintaining the labeled minimum effective dose even at the upper boundary of 50 lbs.
- Chewable format acceptance: In a 115-dog field palatability study, 108 dogs accepted the chewable from the owner’s hand on the first offer, a relevant advantage for medium-breed dogs in this weight range that are difficult to manually pill.
- Single annual purchase option: The product is available in 12-tablet packs, covering a full 12-month prevention cycle without the need for repeated reordering across the heartworm season.
Caution
Hazards to Humans
Not for human use. Keep out of reach of children. Wash hands thoroughly after handling. Avoid contact with eyes. Do not store near food, beverages, or animal feed.
Hazards to Domestic Animals
Administer orally only. This variant is labeled for dogs and puppies weighing 25.1 to 50 lbs (11 to 22 kg) from six weeks of age; do not administer to dogs below this weight or age threshold. Use with caution in debilitated, aged, pregnant, or nursing animals; seek veterinary assessment before dosing in these cases. Rare individual sensitivity to milbemycin oxime or praziquantel has been documented across study populations. Consult a veterinarian before concurrent use with other antiparasitic agents or any drugs known to interact with macrocyclic lactones, including P-glycoprotein inhibitors.
Possible Side Effects
Monitor your dog during the hours following each monthly dose, noting any change in activity level, gait, or gastrointestinal function.
Adverse reactions were not recorded in field acceptability studies at the labeled dose; the following signs have been identified across safety and efficacy studies conducted under NADA 141-338.
- Oral and gastrointestinal reactions: Vomiting was documented across multiple laboratory cohorts, including one dog in the field palatability study that vomited immediately after tablet acceptance. Soft feces and diarrhea were observed at broadly comparable rates in both treated and control groups at the standard dose, indicating limited drug-specific contribution at the labeled level.
- Neurological signs at supratherapeutic doses: Ataxia, decreased activity, salivation, and tremors appeared at 3 and 5 times the maximum labeled dose in repeat-dose safety studies; these signs emerged within the first 24 hours post-dosing and resolved without treatment. At the labeled 1x dose in a puppy cohort, a single instance of ataxia was recorded in one animal across the study group.
- Isolated post-dose findings: One dog in a tapeworm efficacy study exhibited abnormal leaning behavior within 24 hours of a standard-dose administration; this observation was not reproduced in any other study population.
If any adverse signs appear following administration at the labeled dose, contact a veterinarian promptly.










Reviews
There are no reviews yet